Omniscan (Gadodiamide)

Omniscan is used in magnetic resonance imaging procedures to improve visualization of anatomical structures and detect pathology.

• Central nervous system imaging: Enhances detection of lesions, tumors, and vascular abnormalities.
• Cardiovascular MRI: Improves delineation of cardiac chambers, vessels, and perfusion defects.
• Whole‑body and oncologic MRI: Provides better contrast for tumor identification and staging.

• Gadodiamide is a gadolinium‑based contrast agent that distributes in the extracellular fluid space after intravenous injection. It shortens the T1 relaxation time of nearby water protons, producing increased signal intensity on T1‑weighted MRI sequences and thereby enhancing the contrast between normal and pathological tissues.

Adverse reactions to gadodiamide‑based contrast agents are generally uncommon but can vary in severity.

Common Side Effects

• Nausea: Mild, transient feeling of stomach upset.
• Headache: Short‑lasting headache following injection.
• Injection site discomfort: Minor pain or burning at the site of administration.
• Warmth sensation: Transient feeling of warmth or flushing.
• Dizziness: Light‑headed feeling that resolves quickly.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): A rare fibrotic disorder in patients with severe renal impairment.
• Anaphylactoid reactions: Severe allergic responses including hives, bronchospasm, or hypotension.
• Severe hypersensitivity: Potential for life‑threatening allergic reaction requiring immediate medical attention.
• Cardiac arrest: Extremely rare but reported in cases of severe anaphylaxis.
• Renal toxicity: Potential worsening of kidney function in susceptible individuals.

When using Omniscan, clinicians should assess patient risk factors and follow recommended safety protocols.

• Renal function assessment: Evaluate glomerular filtration rate before administration.
• Allergy history: Review prior reactions to gadolinium‑based agents.
• Hydration status: Ensure adequate patient hydration to facilitate renal clearance.
• Pregnancy considerations: Use only if clearly needed, after risk‑benefit evaluation.
• Pediatric use: Adjust dosing based on weight and monitor closely.
• Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Gadodiamide may interact with other substances that affect renal function or cause hypersensitivity.

Major Interactions (Avoid)

• Loop diuretics: May exacerbate renal impairment, increasing NSF risk.
• High‑dose intravenous iron: Can alter gadolinium clearance and increase toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): May reduce renal perfusion, requiring closer monitoring of kidney function.
• Metformin: May need temporary discontinuation in patients with reduced renal function to avoid lactic acidosis.
• Other contrast agents: Stagger administration to prevent cumulative gadolinium exposure.
• Antihistamines: May mask early signs of an allergic reaction, requiring vigilant observation.